JAK-Inhibition in Immune-Mediated Diseases (IMiDs)

Interdisciplinary Approaches to IMID Management: Addressing Shared Pathophysiology With JAKisПодробнее

IBD Medications: JAK InhibitorsПодробнее

Rheumatology Author Andreas Kerschbaumer: JAK InhibitorsПодробнее

Insights at EULAR 2020: Safety of JAK InhibitorsПодробнее

The Expanding Role of JAK Inhibitors Across IMIDsПодробнее

Why Personal Behavior Affects Immune Mediated Inflammatory DiseasesПодробнее

Immune-mediated inflammatory diseases (IMIDs) and Therapeutic antibodies versus small moleculesПодробнее

Insights at EULAR 2020: Clinical Data on JAK InhibitorsПодробнее

Discussing Rheumatology: JAK InhibitorsПодробнее

Strategies for Improving IMID Outcomes: The Potential of JAK InhibitorsПодробнее

A toolkit for immune mediated inflammatory disease precision medicineПодробнее

Forum LIVE: Considerations for the Optimal Use of JAKiПодробнее

Discussing RA: Navigating JAKis, TNFis, and the quest for optimal RA therapyПодробнее

Immune-mediated inflammatory diseases (IMIDs) - ENOTTA WebinarПодробнее

Optimizing outcomes in IMIDs: Focus on Co-MorbiditiesПодробнее

Novel JAK Inhibitors Under Investigation for IBDПодробнее

Discussing RA: January 2024Подробнее

Basic and Clinical Immunology for the Busy Clinician – Part IIПодробнее

JAK inhibitors for IBDПодробнее

Biologics Across Immune-Mediated Inflammatory Diseases from the Rheumatology PerspectiveПодробнее